Replimune Group, Inc. (REPL) has encountered a major hurdle as the U.S. Food and Drug Administration (FDA) rejected its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec), a drug candidate aimed at treating melanoma. This rejection marks the second time the FDA has turned down the application, primarily due to concerns regarding the effectiveness of the drug and flaws in the trial design. The FDA found the IGNYTE study too heterogeneous and deemed the confirmatory study insufficient. Following this news, Replimune's stock experienced a sharp decline, raising doubts about its near-term prospects. Additionally, the company may face financial challenges, with its cash runway potentially lasting less than 12 months. As a result, Replimune might need to restructure or reprioritize its resources, possibly shifting focus to RP2, which targets metastatic uveal melanoma. Given these ongoing regulatory hurdles and uncertain funding, analysts suggest that this is not an opportune moment to invest in Replimune.